Изучение функциональной активности глюкозаминилмурамоилдипептида на опухолевых клетках
Диссертация
Мурамилпептиды представляют собой фрагменты пептидогликана муреина — главного структурного компонента клеточной стенки всех бактерий. Это макромолекула, в состав которой входят линейные полисахаридные цепи, которые соединены через лактильные остатки мурамовой кислоты короткими олигопептидными фрагментами. В результате формируется жесткий двумерный каркас. Этот каркас окружает бактериальную клетку… Читать ещё >
Содержание
- СПИСОК ИСПОЛЬЗУЕМЫХ СОКРАЩЕНИЙ
- ГЛАВА 1. ЛИТЕРАТУРНЫЙ ОБЗОР. Противоопухолевая активность мурамилпептидов. 7 I. Противоопухолевая активность МП in vitro и in vivo
- Ы.МДПиГМДП
- 1. 2. Аналоги с модифицированной N-ацетилмурамовой кислотой
- 1. 3. Аналоги с заменой остатка L-аланина
- 1. 4. Аналоги с модификацией остатка D-изоглутамина
- 1. 5. Инкапсулированные МП 12 II. Механизм противоопухолевого действия МП 16 II. 1. Активация макрофагов
- 11. 2. Увеличение активности нормальных киллеров
- 11. 3. Повышение активности нейтрофилов, лимфоцитов и эндотелиальных клеток
- 11. 4. Индукция биосинтеза цитокинов
- II. 5. Прямое действие на опухолевые клетки
- III. Применение МП в комплексной терапии 23 III. 1. Задачи комплексной терапии
- 111. 2. Комбинация МП/химиопрепарат
- 111. 3. Комбинация МП/цитокин
- 111. 4. Комбинация МП/липополисахарид 35 IV. Использование МП в клинике
- 2. 1. ГМДП индуцирует секрецию TNF-a, который повышает чувствительность популяции клеток меланомы BRO к восприятию сигнала ГМДП
- 2. 2. TNF-a увеличивает число сайтов специфического связывания ГМДП на клетках меланомы BRO
- 2. 3. Демаскирование как механизм увеличения числа сайтов специфического связывания ГМДП на поверхности клеток меланомы BRO
- 2. 4. Влияние ГМДП и TNF-a на жизнеспособность клеток TNFa-резистентных и TNFa-чувствительных клеточных линий in vitro
- 2. 4. 1. Влияние ГМДП на цитотоксическое действие r-TNF-a в отношении клеток линии L
- 2. 4. 2. Цитотоксическое действие аналогов ГМДП и Акт D, на клетки линии L
- 2. 4. 3. Влияние ГМДП на цитотоксический эффект цисплатина и доксорубицина в отношении клеток линии L
- 2. 4. 4. Влияние ГМДП на цитотоксическое действие комбинаций r-TNF-a с цитостатиками проявленное в отношении клеток линии L
- 2. 4. 5. Влияние аналогов ГМДП на цитотоксический эффект TNF-a в присутствии актиномицина D в отношении клеток линии L
- 2. 4. 6. Влияние ГМДП на цитотоксический эффект комбинаций цисплатин /TNF-a и доксорубицин /TNF-a в отношении клеток линии L
- 2. 4. 7. Влияние комбинаций ГМДП, цисплатина и TNF-a на жизнеспособность трансформированных клеток TNFa-чувствительных линий человека и мыши
- 2. 4. 8. Влияние ГМДП и TNF-a на жизнеспособность TNF-a-резистентных клеточных линий in vitro
- 2. 4. 9. Влияние комбинаций препаратов ГМДП, r-TNF-a и цисплатина на опухолевые клетки онкологических больных
- 2. 4. 10. Влияние комбинаций препаратов ГМДП, цисплатин и TNF-a на нормальные клетки
- 2. 4. 11. Влияние комбинаций препаратов ГМДП, доксорубицин и TNF-a на жизнеспособность нормальных клеток и трансформированных клеток
Список литературы
- Freund J. The mode of action of immunologic adjuvants. (1956) Adv. Tuberulogy Res (Basel). 7,130−148.
- Kusumoto S., Tarumi Y., Ikenaka K., Shiba T. Chemical synthesis of N-acetyl-muramyl peptides with partial structures of bacterial cell wall and their analogs in relation of immunoadjuvant activity. (1975) Bull. Chem. Soc.Jap., 49, 533−539.
- Fidler I.J., Sone S., Fogler W.E., Barnes Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes, containing muramyl dipeptide. (1981) Proc.Natl.Acad.Sci.USA, 78,1680−1687.
- Lefrancier P., Lederer E. Muramyl-peptides. (1987) Pure&Appl.Chem., 59(3), 449−454.
- Иванов B.T. Иммуноактивные пептиды. (1984) Вопросы медицинской химии, 30, 23−31. Bogdanov I.G., Dalev P.G., Gurevich A.I. Antitumour glycopeptides from Lactobacillus bulgaricus. (1975) FEBS Letters, 57, 259−261).
- Ростовцева Л.П., Андронова T.M., Малькова В. Г., Сорокина И. Б., Иванов В. Т., Синтез и противоопухолевое действие гликопептидов, содержащих №ацетилглюкозаминил-(Р1−4)-N-ацетилмурамил- дисахаридное звено. (1981) Биоорганическая химия, 7(12), 1843−1858.
- Taniyama Т, Holden НТ. Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide. (1979) Cell Immunol. 48(2), 369−74.
- Sone S, Mutsuura S, Ogawara M, Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. (1984) J Immunol, 132(4), 2105−10.
- Bubenik J, Jezek J, Zaoral M, Hofmann J, Gruntenko YV, Osipov JG, Zolotareva AG, Vakhrusheva ТЕ, Budker VG. Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide. (1984) Cancer Immunol Immunother, 18(2), 123−5.
- Phillips NC, Tsao MS. Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice. (1991) Cancer Immunol Immunother, 33(2), 85−90
- Parant M, Parant F, Chedid L, Yapo A, Petit JF, Lederer E. Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. (1979) Int J Immunopharmacol, l (l), 35−41
- Ambler L, Hudson AM. Pharmacokinetics and metabolism of muramyl dipeptide and nor-muramyl dipeptide 3H-labelled. in the mouse. (1984) Int J Immunopharmacol, 6(2), 133−9.
- Daemen T, Dontje BH, Veninga A, Scherphof GL, Oosterhuis WL. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. (1990) Sel Cancer Ther, 6(2), 6371.
- Acevedo HF, Raikow RB, Acevedo HO, Delgado TF, Pardo M. Prevention of oncogenic viral infections in mice with CGP a synthetic muramyl dipeptide analog. (1985) Antimicrob Agents Chemother, 28(5), 589−96.
- Azuma J., Sugimura K., Yamawaki M., Kusumoto S., Okada S., Shiba Т., Yamamura Y. Adjuvant activity of synthetic 6-o-'Mycolyl"-N-acetylmuramyl-L-alanyl D-isoglutamine and related compounds. (1978) Infect.Immun. 20, 600−607.
- Ivanov V., Andronova Т., Bezrukov M., Makarov E., Kozmin S., Astapova M., Barkova Т., Nesmeyanov V. Structure, design, and synthesis immunoactive peptides. (1987) Pure & Appl. Chem. 59,317−324.
- Pinegin В. V. US5877147: Compounds for medicinal use, March 2,1999.
- Karsonova MI, Andronova TM, Pinegin BV, Khaitov RM. The immunostimulating activity of muramyl dipeptide and its derivatives. (1999) Zh Mikrobiol Epidemiol Immunobiol. May-Jun,(3), 104−10.
- JO.Yokouchi J, Hirabayashi S, Kanesaka N, Baba S, Amino M, Abe K. Study on the most appropriate time for Romurtide administration (Nopia) in radiotherapy patients. (1997) Gan To Kagaku Ryoho., 24(13), 1967−73.
- Kawamori J, Saito T, Maeno T, Muto H. Effectiveness of thrice-weekly injection of romurutide for prophylaxis of leukocytopenia during radiation therapy. (1994) Gan To Kagaku Ryoho., 21(7), 1057−62.
- Azuma I. Review: inducer of cytokines in vivo: overview of field and romurtide experience. (1992) Int J Immunopharmacol, 14(3), 487−96.
- Namba K, Yamamura E, Nitanai H, Otani T, Azuma I. Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. (1997) Vaccine., 15(4), 405−13.
- Furuse K, Sakuma A. Activation of the cytokine network by muroctasin as a remedy for leukopenia and thrombopenia. (1989) Arzneimittelforschung., 39(8), 915−7.
- Fidler I.J., Sone S., Fogler W.E., Smith D. Efficacy of liposomes, containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. (1982) J.Biol.Response Modif., 1, 43−55.
- U .Fidler I J. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. (1986) Cancer Immunol Immunother, 21(3), 169−73.
- Talmadge JE, Lenz BF, Klabansky R, Simon R, Riggs C, Guo S, Oldham RK, Fidler IJ Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. (1986) Cancer Res, 46(3), 1160−3.
- MacEwen EG, Kurzman ID, RosenthalRC, Smith BW, Manley PA, Roush JK, Howard PE. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. (1989) J Natl Cancer Inst, 81(12), 935−8.
- Umanskii VIu, Stefanov AV, Bondar' OP, Balitskii KP, Pinchuk VG. Antimetastatic effect of a liposome-enclosed analog of muramyl dipeptide. (1988) Vopr Onkol, 34(4), 433−8.
- Umanskii VIu, Stefanov AV, Bondar' OP, Braginskii SA, Balitskii KP. spread of Lewis lung carcinoma. Effect of GMDP encapsulated into liposomes on metastatic] (1988) Eksp Onkol 1988,10(5), 40−3.
- Phillips NC, Stewart-Phillips J, Wang P. Tumor cell binding and induction of endothelial cell tumoricidal activity in vitro by muramyl dipeptide is enhanced by liposomal encapsulation. (1994) J Immunother Emphasis Tumor Immunol, 15(3), 185−93.
- Kleinerman ES, Erickson KL, Schroit A J, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. (1983) Cancer Res, 43(5), 2010−4.
- Morin C, Barratt G, Fessi H, Devissaguet JP, Puisieux F. Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules. (1994) Int J Immunopharmacol., 16(5−6), 451−6.
- Barratt G, Puisieux F, Yu WP, Foucher C, Fessi H, Devissaguet JP. Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. (1994) Int J Immunopharmacol., 16(5−6), 457−61.
- Asao T, Shibata HR, Batist G, Brodt P Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin. (1992) Cancer Res, 52(22), 6254−7.
- Malik ST, Martin D, Hart I, Balkwill F. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. (1991) Br J Cancer, 63(3), 399−403.
- Brownbill AF, Braun DG, Dukor P, Schumann G Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide. (1985) Cancer Immunol Immunother, 20(1), 11−7.
- Brownbill AF, Schumann G. MTP-PE: induction of tumoricidal leukocytes in the lungs of rats. (1988) Cancer Detect Prev, 12(1−6), 161−8.
- Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. (1995) Hematol Oncol Clin North Am, 9(4), 927−38.
- Azuma I, Ogawa Y, Igari Y, Ukei S, Yamamura Y Antitumor activity on line 10 hepatoma in strain 2 guinea pigs and pharmaceutical properties of quinonyl-MDP preparations. (1986) Methods Find Exp Clin Pharmacol, 8(l), 15−8.
- Khaidukov S.V., Komaleva R.L. and Nesmeyanov V.A. N-Acetylglucosamine-Containg Muramyl Peptides Directly Affect Macrophages. (1995) Int.J.Immunopharmac., 17(11), 903 911.
- Smith BW, Kurzman ID, Schultz KT, Czuprynski CJ, MacEwen EG Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. (1993) Cancer Biother, 8(2), 137−44.
- Sone S, Utsugi T, Tandon P, Yanagawa H, Okubo A, Ogura T. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients. (1990) Cancer Immunol Immunother, 30(6), 357−62.
- Talmadge JE, Schneider M, Collins M, Phillips H, Herberman RB, Wiltrout RH. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. (1985) J Immunol, 135(2), 1477−83.
- Sosnowska D, Mysliwski A, Dzierzbicka K, Kolodziejczyk AM. The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (natural killer) cells from hamsters bearing Ab Bomirski melanoma. (1997) Biotherapy, 10(2), 161−8.
- Sakita M, Kageyama N, Majima S. Comparative studies between liposomes containing muramyl dipeptide and various immunomodulators on activation of mouse peritoneal macrophages and NK cells. (1985) Oncology, 42(4), 259−64.
- BO.Maini A, Morse PD, Wang CY, Jones RF, Haas GP. New developments in the use of cytokines for cancer therapy. (1997) Anticancer Res, 17(5B), 3803−8.
- В1 .Tartour E, Fridman WH. Cytokines and cancer. Int Rev Immunol 1998,16(5−6), 683−704.
- Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. (1993) J Immunother, 14(4), 286−92.
- Ройт А., Бростоф Дж., Мейл Д. Иммунология. Москва: «Мир», 2000, с. 183
- Maeda М, Knowles RD, Kleinerman ES Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. (1991) Cancer Commun, 3(10−11), 313−21.
- Kurzman ID, Shi F, MacEwen EG .In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide. (1993) Vet Immunol Immunopathol, 38(1−2), 45−56.
- Hoedemakers RM, Morselt HW, Scherphof GL, Daemen T. Secretion pattern of the rat liver macrophage population following activation with liposomal muramyl dipeptide in vivo and in vitro. (1994) J Immunother Emphasis Tumor Immunol, 15(4), 265−72.
- Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW 2d, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, et al. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. (1990) Cancer Res, 50(10), 2979−86.
- Favaro D, Santarosa M, Quaia M, Spada A, Freschi A, Talamini R, Galligioni E Soluble intercellular adhesion molecule-1 and serum cytokines in melanoma patients treated with liposomes containing muramyl tripeptide. (1995) Tumori, 81(3), 185−90.
- Несмеянов В.А. Цитокины иммунной системы, в кн. «Белки иммунной системы», под ред. ИвановаВ.Т. Москва, 1997, с. 79−120.
- Namba К, Yamamura Е, Nitanai Н, Otani Т, Azuma I Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. (1997) Vaccine, 15(4), 405−13.
- Валякина Т.И., Малахов А. А., Макаров E.A., Андронова T.M., Ревазова E.C., Несмеянов В. А., Иванов В. Т. Мурамилпептиды модулируют экспрессию опухолеассоциированных антигенов. (1993) Иммунология, 4, с. 32−36.
- Nesmeyanov VA, Khaidukov SV, Komaleva RL, Andronova TM, Ivanov VT. Muramylpeptides augment expression of la-antigens in mouse macrophages. (1990) Biomed Sci., 1, 151−4.
- Ю.Хэнни К. Джиллис С. Клеточная цитотоксичность. Иммунология под ред. Пола У. Москва «Мир» 1989, Т. З, с. 142−145.
- Todd RF 3rd, Alvarez PA, Brott DA, Liu DY. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, МоЗе. (1985) J Immunol, 135(6), 3869−77.
- Liu DY, Ree JY, Trochelman RD, Todd RF 3rd. Identification of a human monocyte antigen (МоЗе) associated with cellular activation and lymphokine responsiveness. (1989) Eur J Immunol, 19(4), 721−7.
- Killion JJ, Fidler IJ. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. (1994) Immunomethods, 4(3), 273−9.
- Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. (1995) Am J Clin Oncol, 18(2), 93−9.
- Wang L, Roos G, Stenram U Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE. (1995) Anticancer Res, 15(5B), 2077−80.
- Noso Y, Becker J, Riveau G, Audibert F, Chedid L Production and enhanced anti-tumor activity of tumor necrosis factor in mice treated with cyclophosphamide. (1990) Jpn J Cancer Res, 81(9), 942−8.
- Killion JJ, Kleinerman ES, Wilson MR, Tanaka M, Fidler IJ Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. (1992) Oncol Res, 4(10), 413−8.
- Carswell E., Old L., Kassel R., Green S., Fiore N. and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. (1975) Proc. Natl. Acad. Sci. U.S.A., 72, 3666−3670.
- ШИЧКИН В. П. Патогенетическое значение цитокинов и перспективы цитокин/антицитокиновой терапии. (1998) Иммунология, 2, 9−13.
- Dinney CP, Tanguay S, Bucana CD, Eve BY, Fidler IJ Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. (1995) J Interferon Cytokine Res, 15(6), 585−92.
- Bahr GM, Pouillart PR, Chedid LA Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. (1996) J Interferon Cytokine Res, 16(4), 297−306.
- Springer ТА. Adhesion receptors of the immune system. (1990) Nature, 346(6283):425−34.
- Fidler IJ, Fogler WE, Kleinerman ES, Saiki I. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes. (1985) J Immunol, 135(6), 4289−96.
- Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. (1983) J Immunol, 130(5), 2011−3.
- Metcalf D, Begley CG, Nicola NA, Johnson GR. Quantitative responsiveness of murine hemopoietic populations in vitro and in vivo to recombinant multi-CSF (IL-3). (1987) Exp Hematol., 15(3), 288−95.
- Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conlon PJ. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. (1986) Science, 232(4749), 506−8.
- Uslu R, Bonavida B. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum. (1996) Cancer, 77(4), 725−32.
- Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G, Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. (1993) EMBO J., 12(8), 3095−104.
- Gaar E, Naziri W, Cheadle WG, Pietsch JD, Johnson M, Polk HC Jr Improved survival in simulated surgical infection with combined cytokine, antibiotic and immunostimulant therapy. (1994) Br J Surg, 81(9), 1309−11.
- Phillips NC, Tsao MS. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. (1989) Cancer Res, 49(4), 936−9.
- BIoksma N, Hofhuis FM, Willers JM. Endotoxin-induced antitumor activity in the mouse is highly potentiated by muramyl dipeptide. (1984) Cancer Lett, 23(2), 159−65.
- Bloksma N, Hofhuis FM, Willers JM. Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor-necrotizing agents. (1984) Cancer Immunol Immunother, 17(3), 154−9.
- Bloksma N, Hofhuis FM, Willers JM. Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin. (1985) Cancer Immunol Immunother, 19(3), 205−10.
- Kleinerman ES, Maeda M, Jaffe N Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. (1993) Cancer Treat Res, 62, 101−7.
- Frost H, Murray JL, Chaudri HA, Van Damme J. Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. (1990) J Biol Response Mod, 9(2), 160−6.
- Gianan MA, Kleinerman ES Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. (1998) Cancer Biother Radiopharm, 13(5), 363−8.
- Vosika GJ, Cornelius DA, Gilbert CW, Sadlik JR, Bennek JA, Doyle A, Hertsgaard D. Phase I trial of ImmTher, a new liposome-incorporated lipophilic disaccharide tripeptide. (1991) J Immunother, 10(4), 256−66.
- Yanagawa H, Haku T, Takeuchi E, Suzuki Y, Nokihara H, Sone S. Intrapleural therapy with MDP-Lys (LI 8), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer. (2000) Lung Cancer, 27(2), 67−73.
- Kaydalov AA, Utkin YuN, Andronova TM, Tsetlin VI, Ivanov VT. Muramyl peptides bind specifically to rat brain membranes. (1989) FEBS Letters, 248(1−2), 78−82.
- Johnson G.D. Immunofluorescence: Antibodies. A Practical Approach. Ed. Catty D. Oxford,
- New York, Tokyo: IRL Press, 1989. V.41. P. 179−200.
- Sumaroka M., Litvinov I., Khaidukov S., Golovina Т., Kamraz M., Komal’eva R., Andronova Т., Makarov E., Nesmeyanov V., Ivanov V. Muramyl peptide-binding sites are located inside target cells. (1991) FEBS Letters, 295,48−50.
- Sahlin S, Hed J, Rundquist I. Differentiation between attached and ingested immune complexes by a fluorescence quenching cytofluorometric assay. (1983) J Immunol Methods, 60(1−2), 11 524.
- Cook JA, Krishna MC, Pacelli R, DeGraff W, Liebmann J, Mitchell JB, Russo A, Wink DA. Nitric oxide enhancement of melphalan-induced cytotoxicity. (1997) Br J Cancer, 76(3), 325−34.
- Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. (1998) Clin Cancer Res., 4(1), 117−30.
- Jupin C, Parant M, Chedid L. Effect of muramyl peptides and tumor necrosis factor on oxidative responses of human blood phagocytes. (1989) Immunol Lett, 22(3), 187−92.
- Williamson B., Carswell A., Rubin В., Prendergast J., Old L. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. (1983) Proc.Natl.Acad.Sci.USA, 80, 5398−5401.
- Mosman T. Rapid colometric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. (1983) J.Immunol. Mrthods, 65, 55−63.
- Alexander R., Nelson W., Coffey D. Synergistic Enhancement by Tumor Necrosis Factor of in Vitro Cytotoxicity from Chemotherapeutic Drugs Targeted at DNA Topoisomerase II. (1987) Cancer Res, 47, 2403−06.
- Lee SH, Aggarwal BB, Rinderknecht E, Assisi F, Chiu H. The synergistic antiproliferative effect ofgamma-interferon and human lymphotoxin. (1984) J Immunol, 133(3), 1083−6.
- Sugaraian BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. (1985) Science, 230(4728), 943−5.
- Beran M, Andersson BS, Kelleher P, Whalen K, McCredie K, Gutterman J. Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines. (1987) Blood, 69(3), 721−6.
- Page M, Bejaoui N, Cinq-Mars B, Lemieux P. Optimization of the tetrazolium-based colorimetric assay for the measurement of cell number and cytotoxicity. (1988) Int J Immunopharmacol, 10(7), 785−93.
- Foultier MT, Vonarx-Coinsmann V, Patrice T, Cloarec D, Xu XN, Combre A. Effects of high glucose concentration on survival and respiration of human endothelial cells. (1992) Biochimie, 74(11), 975−9.
- York JL, Maddox LC, Zimniak P, McHugh ТЕ, Grant DF. Reduction of MTT by glutathione S-transferase. (1998) Biotechniques, 25(4), 622−4,626−8.
- Melzig M, Dienwiebel U. Is the estimation of the activity of MTT-reduction suitable for the determination of basal cytotoxicity? (1990) Pharmazie, 45(7), 515−7.
- Брызгалов И.П., Галецкий C.A., Юдичева T.B., Ревазова Е. С. (1994) Бюл. экспер. Медицины, 8, 184−187.
- Haranaka К., Satomi N., Sakuray A. Antitumor Activity of Murine Tumor Necrosis Factor (TNF) against Transplanted Murine Tumors and Heterotransplanted Human Tumors in Nude Mice. (1984) Int. J. Cancer, 34,263−267.
- Shirai T. et al., Cloning and Expression in Escherichia coli of the Gene for Human Tumor Necrosis Factor. (1985) Nature, 313,803−806.
- Wang M. Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor. (1985) Science, 228,149−154.
- Sander, В., Boeryd, B. Tumor necrosis factor-alpha expression in human primary malignant malanoma and it relationship to tumor infiltration by CD3+ cells. (1996) Int. J. Cancer, 66, 42−47.
- Goillot, E., Combaret, V., Ladenstein, R., Baubet, D., Blay, J., Philip, T. and Favrot, M. Tumor Necrosis Factor as an autocrine growth factor for neuroblastoma. (1992) Cancer Res. 52, 31 943 200.
- Himeno T, Watanabe N, Yamauchi N, Maeda M, Tsuji Y, Okamoto T, Neda H, Niitsu Y. Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor. (1990) Cancer Res., 50(16), 4941−5.
- Rosenblum MG, Cheung L, Murray JL, Bartholomew R. Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. (1991) Cancer Commun, 3(l), 21−7.
- Spriggs, D., Imamura, K., Rudriguer, C., Sariban, E. and Kafe, D. Tumor necrosis factor expression in human epithelial tumor cell lines. (1988) J. Clin. Invest. 81,455−460.
- Gamble J.R., Smith W.B., and Vadas M.A. (1992) in B. Beutler (Ed.), Tumor Necrosis Factors: The molecular and their emerging role in medicine, Raven Press, Ltd., New York, p. 65−86.
- Clauss M., Ryan J., and Stern D. (1992) in B. Beutler (Ed.), Tumor Necrosis Factors: The molecular and their emerging role in medicine, Raven Press, Ltd., New York, p. 65−86.
- Vanhaesebroeck B, Mareel M, Van Roy F, Grooten J, Fiers W. Expression of the tumor necrosis factor gene in tumor cells correlates with reducedtumorigenicity and reduced invasiveness in vivo. (1991) Cancer Res., 51(8), 2229−38.
- Eigler A., Sinha Bh., Hartmann G., Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. (1997) Immunology today, 18,487−492.
- Golovina Т., Sumaroka M., Samokhvalova L., Shebzukhov Yu., Andronova Т., Nesmeyanov V. Biochemical characterization of glucosaminilmuramyl dipeptide binding sites of murine macrophages. (1994) FEBS Letters, 356,9−12.
- Golovina T, Fattakhova G, Swiderek K, Makarov E, Bovin N, Shively J, Nesmeyanov V. Specific binding of glucosaminylmuramyl peptides to histones. (1999) FEBS Letters, 454(l-2), 152−6.
- Fogler WE, Fidler IJ The activation of tumoricidal properties in human blood. monocytes by muramyl dipeptide requires specific. intracellular interaction. (1986) J Immunol, 136(6), 2311−7.
- Silverman D., Krueger J., Karnovky M. Specific Binding Sites for Muramyl Peptides on Murine Macrophages. (1986) J.Immunol., 136,2195−2201.
- Fogler WE, Fidler IJ. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. (1987) Int J Immunopharmacol, 9(2), 141−50.
- Nesmeyanov V.A., Golovina T.N., Khaidukov S.V., Shebzuchov Y.V. in Peptides in Immunology. Ed. Schneider C.H. Chichester: John Wiley and Sons, 1996. P. 291−294.
- Tenu JP, Adam A, Souvannavong V, Yapo A, Petit JF, Douglas K. Photoaffinity labelling of macrophages and B-lymphocytes using 1251-labelled aryl-azide derivatives of muramyldipeptide. (1989) Int J Immunopharmacol., 11(6), 653−61.
- Weidemann B, Schletter J, Dziarski R, Kusumoto S, Stelter F, Rietschel ET, Flad HD, Ulmer AJ. Specific binding of soluble peptidoglycan and muramyldipeptide to CD 14 on human monocytes. (1997) Infect Immun, 65(3), 858−64.
- Dziarski R., Tapping R.I., Tobias P. S. Binding of Bacterial Peptidoglycan to CD14. (1998) J Biol Chem 1998,273(15), 8680−8690.
- Codington JF, Frim DM. Cell-surface macromolecular and morphological changes related to allotransplantability in the ТАЗ tumor. (1983) Biomembranes, 11, 207−58.
- Suffys P, Beyaert R, Van Roy F, Fiers W. Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity. (1988) Eur J Biochem., 178(1), 257−65.
- Сологуб Л.И., Пашковская И. С., Антоняк Г. Л. Участие протеиназ в инвазии злокачественных опухолей. (1992) Эксперим. Онкология, 14(6), 7−12.
- Matsunaga К, Mashiba H. Augmentation of in vitro cytotoxicity and in vivo tumor-inhibition by combined use of lymphotoxin-containing supernatants and antitumor drugs. (1983) Cancer Lett., 20(1), 21−8.
- Fung KP, Leung SW, Ha DK, Ng SW, Choy YM, Lee CY Effect of tumour necrosis factor on growth of Ehrlich ascites tumour cells in vitro and in vivo. (1985) Cancer Lett, 27(3), 269−76.
- Mutch DG, Powell CB, Kao MS, Collins JL. In vitro analysis of the anticancer potential of tumor necrosis factor in combination with cisplatin. (1989) Gynecol Oncol, 34(3), 328−33.
- Lienard D, Ewalenko P, Delmotte J, Renard N, Lejeune F. High-Dose Recombinant Tumor Necrosis Factor alfa in Combination With Interferon gamma and Melphalan in Isolation Perfusion of the Limbs for Melanoma and Sarcoma. (1992) J Clin Oncol, 10, 52−60.
- Matsui H, Suzuka K, Iitsuka Y, Seki K, Sekiya S Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. (2000) Gynecol Oncol, 78(l), 28−31.
- Sella A, Aggarwal BB, Kilbourn RG, Bui CA, Zukiwski AA, Logothetis CJ. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. (1995) Cancer Biother, 10(3), 225−35.
- Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. (1994) J Biol Chem., 269(2), 787−90.
- Lentz, M. Wo9961085a2: Method and compositions for treatment of cancers.
- Ю-Rossi CR, Foletto M, Di Filippo F, Vaglini M, Anza' M, Azzarelli A, Pilati P, Mocellin S, Lise M. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. (1999) Cancer, 86(9), 1742−9.
- Maranda E, Robak T Interactions of 2', 2'-diflurodeoxycytidine (gemcitabine) with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388. (1998) Arch Immunol Ther Exp (Warsz), 46(2), 113−9.
- Warzocha K, Robak T Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia LI210 and leukemia P388 in mice. (1992) Acta Haematol Pol, 23(1), 55−62.
- Ujhazy P, Chen YF, Fredericks W, Ho RL, Mihich E, Baker RM, Ehrke MJ The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model. (1990) Cancer Commun, 2(5), 181−8.